Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study
NAT is an independent risk factor for clinically relevant chyle leak following PDAC resection. These findings highlight the need for risk-adapted postoperative management and warrant prospective validation.
Authors
- Thilo Hackert (ORCID: https://orcid.org/0000-0002-7012-1196)
- Thomas Hank (ORCID: https://orcid.org/0000-0001-8087-2295)
- Georgios Polychronidis (ORCID: https://orcid.org/0000-0002-9819-8179)
- Ulf Hinz (ORCID: https://orcid.org/0000-0001-8227-968X)
- Martin Schneider (ORCID: https://orcid.org/0000-0001-5907-3587)
- Oliver Strobel (ORCID: https://orcid.org/0000-0001-5100-8449)
- Carl-Stephan Leonhardt (ORCID: https://orcid.org/0009-0001-7179-9580)
- Mohammed Al‐Saeedi (ORCID: https://orcid.org/0000-0002-0583-4472)
- Markus W. Buechler
- Martin Loos
- Sakher Shraim
Institutions
- Champalimaud Foundation (PT)
- Universität Hamburg (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1245/s10434-025-18698-4
- Citations
- 1
- Primary Topic
- Lymphatic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01